NCT04238637 - Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG

Durvalumab

Durvalumab IV (intravenous Infusion)

DRUG

Tremelimumab

Tremelimumab IV (intravenous Infusion)

Trial Locations (8)

NOT_YET_RECRUITING

University Hospital Dresden, Dresden

COMPLETED

Clinic Essen Center, Essen

NOT_YET_RECRUITING

University Hospital Essen, Essen

RECRUITING

University Hospital Halle, Halle

RECRUITING

Hannover Medical School, Hanover

RECRUITING

University Hospital Jena, Jena

NOT_YET_RECRUITING

Munich Clinic Bogenhausen, Munich

NOT_YET_RECRUITING

University Hospital Munich Grosshadern, Munich